HomeCompareGILD vs TGS

GILD vs TGS: Dividend Comparison 2026

GILD yields 2.34% · TGS yields 2.74%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TGS wins by $267.47M in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
TGS
TGS
● Live price
2.74%
Share price
$34.68
Annual div
$0.95
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$267.50M
Annual income
$249,968,045.94
Full TGS calculator →

Portfolio growth — GILD vs TGS

📍 TGS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDTGS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + TGS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
TGS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
TGS
Annual income on $10K today (after 15% tax)
$232.84/yr
After 10yr DRIP, annual income (after tax)
$212,472,839.05/yr
At 15% tax rate, TGS beats the other by $212,471,466.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + TGS for your $10,000?

GILD: 50%TGS: 50%
100% TGS50/50100% GILD
Portfolio after 10yr
$133.76M
Annual income
$124,984,830.42/yr
Blended yield
93.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
TGS
Analyst Ratings
2
Buy
1
Sell
Consensus: Buy
Altman Z
3.1
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
TGS buys
0
No recent congressional trades found for GILD or TGS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDTGS
Forward yield2.34%2.74%
Annual dividend / share$3.19$0.95
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%100%
Portfolio after 10y$29.1K$267.50M
Annual income after 10y$1,614.90$249,968,045.94
Total dividends collected$7.6K$266.18M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy

Year-by-year: GILD vs TGS ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrTGS PortfolioTGS Income/yrGap
1← crossover$10,974$274.45$11,248$547.87$274.00TGS
2$12,073$330.19$13,187$1,151.84$1.1KTGS
3$13,316$398.20$16,634$2,524.15$3.3KTGS
4$14,730$481.49$23,750$5,951.38$9.0KTGS
5$16,345$583.87$41,295$15,882.70$24.9KTGS
6$18,199$710.26$95,805$51,618.57$77.6KTGS
7$20,340$866.96$326,351$223,840.07$306.0KTGS
8$22,826$1,062.22$1,774,419$1,425,223.14$1.75MTGS
9$25,731$1,306.80$16,383,022$14,484,394.34$16.36MTGS
10$29,147$1,614.90$267,497,880$249,968,045.94$267.47MTGS

GILD vs TGS: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

TGSStock

Transportadora de Gas del Sur S.A. engages in transportation of natural gas, production, and commercialization of natural gas liquids in Argentina. The company operates through four segments: Natural Gas Transportation Services; Liquids Production and Commercialization; Other Services; and Telecommunications. The Natural Gas Transportation segment transports natural gas through 5,769 miles of pipeline system to distribution companies, power plants, and industrial customers. It also provides operation and maintenance services for the natural gas transportation facilities. The company's Liquids Production and Commercialization segment produces and commercializes natural gas liquids, such as ethane, liquid petroleum gas, natural gasoline, propane, and butane in Argentina and internationally. Its Other Services segment offers midstream services, including natural gas treatment, separation, and removal of impurities from the natural gas stream, as well as natural gas compression. It also provides services related to pipeline and compression plant construction, operation, and maintenance; and generates steam for electricity production. The Telecommunications segment provides telecommunication services with a network that includes a microwave digital network with synchronous digital hierarchy technology and a dark fiber optic network. As of December 31, 2021, it served 6.2 million residential, commercial, industrial, and electric power generation end users. The company was founded in 1992 and is headquartered in Buenos Aires, Argentina. Transportadora de Gas del Sur S.A. is a subsidiary of Compañía de Inversiones de Energía S.A.

Full TGS Calculator →
📬

Get this GILD vs TGS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.